Cellectis and Servier Announce Collaboration in Alloganeic Cell Therapy : UCART19 to treat lukimia and 5 product candidates targeting solid tumors

PRESS RELEASE

February 17, 2014 - Cellectis (Alternext: ALCLS), an expert of alloganeic CAR T-cell therapies, today announced that it has signed a strategic collaboration agreement with Servier, the first independent French pharmaceutical research company, to develop and commerciallize novel product candidates targeting leukimia and solid tumors.

Silahkan klik di sini untuk informasi lebih detail.

For more information, please contact :

Cellectis
Philippe Valachs
Phone : +33 (0)1 81 69 16 00
 
Servier
Servier Communication Department
Phone : +33 (0)1 55 72 60 37
-----------------------------------------------------------